Drugs such as semaglutide (Ozempic) and liraglutide (Victoza) decrease nucleus accumbens dopamine release and cue-induced craving (Sorensen et al., 2023).
Shared signaling with metabolic regulation suggests overlap between energy balance and reward drive.
May reduce compulsive intake, stress eating, and substance craving.
Illustrate cross-talk between body homeostasis and motivational circuits.
Bruns, IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target, 2024
- Narration cue:
“GLP-1 agonists remind us that addiction is not separate from appetite—it’s the hunger for safety, for relief.”
Subscribe
Login
0 Comments
Oldest
